https://www.selleckchem.com/products/oleic-acid.html There are few reports of hemolytic disease of the fetus and newborn (HDFN) caused by maternal autoantibodies. We describe the case of a pregnant patient aged 26 years with systemic lupus erythematosus without any transfusion history who developed autoantibody with mimicking anti-E specificity. Her newborn developed HDFN caused by the maternal autoantibody. The clinical symptoms of the newborn were not serious. After bilirubin light phototherapy and other symptomatic supportive treatment, the baby was discharged with a good prognosis. This is the first reported case of HDFN caused by maternal autoantibody with mimicking anti-E specificity. However, the real antigenic target of the autoantibody was not clear. This is the first reported case of HDFN caused by maternal autoantibody with mimicking anti-E specificity. However, the real antigenic target of the autoantibody was not clear. Increased serum interleukin 17 (IL-17) concentration has been associated with the immunopathogenesis of autoimmune hemolytic anemia in humans. No data are available about IL-17 in immune-mediated hemolytic anemia (IMHA) of dogs. Monitor changes in serum IL-17 concentration during the acute stages of IMHA in dogs, compared with results in healthy dogs, and its relationship with outcome. Thirty-one client-owned dogs with primary IMHA and 27 healthy dogs. Quantification of serum IL-17 concentration using a commercially available ELISA kit at the time of admission (D0), after 48 hours (D2) and after 96 hours (D4) as compared to concentration in healthy dogs. The IMHA dogs were classified as survivors if discharged from hospital, or nonsurvivors for any cause of in-hospital mortality. Mean serum IL-17 concentration was higher in dogs with IMHA on admission compared with healthy dogs (D0), but this difference was not significant (mean, 19.52 pg/mL vs 10.52 pg/mL, respectively, P = .17). Throughout hospitalization, serum IL-17 concentration sig